AstraZeneca gets US FDA nod for FARXIGA to treat chronic kidney disease EP News Bureau May 1, 2021 In DAPA-CKD Phase III trial, FARXIGA demonstrated reduction in the risk of the composite of worsening of renal function, end-stage…
Diabetes drug, Dapagliflozin shows benefits in patients with CKD EP News Bureau Aug 31, 2020 The drug, on top of standard of care, reduced the composite measure of worsening of renal function or risk of cardiovascular (CV)…
